Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC)

Journal of Leukocyte Biology

Volumn 94, Issue 6, 2013, Pages 1201-1206

  McCarthy, Fiona ^a   Roshani, Rozita ^a   Steele, Jeremy ^b   Hagemann, Thorsten ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Immunotherapeutic agents; Malignancies; Progression free survival; Tumor

Indexed keywords

BELAGENPUMATUCEL; BMS 936559; CANCER VACCINE; CIMAVAX EGF; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EMEPEPIMUT S; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TG 4010; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; DRUG RESEARCH; DRUG TARGETING; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

IMMUNOTHERAPEUTIC AGENTS; MALIGNANCIES; PROGRESSION-FREE SURVIVAL; TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 84888813447     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0313121     Document Type: Review

References (55)

1. Hanahan, D., Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
2. Hanahan, D., Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
3. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Garbe, C., Lebbe, C., Baurain, J. F., Testori, A., Grob, J. J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller W. H., Jr., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T. T., Humphrey, R., Hoos, A., Wolchok, J. D. (2011) Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.
4. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., Schellhammer, P. F. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
5. World Health Organization (January 2013) Media centre. "Cancer", Vol. 2013, Fact sheet No. 297, http://www.who.int/mediacentre/factsheets/fs297/en/.
6. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., Adjei, A. A. (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594.
7. Crino, L., Weder, W., van Meerbeeck, J., Felip, E. (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v103-v115.
8. Shepherd, F. A., Douillard, J. Y., Blumenschein G. R., Jr., (2011) Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J. Thorac. Oncol. 6, 1763-1773.
9. Kelly, R. J., Giaccone, G. (2011) Lung cancer vaccines. Cancer J. 17, 302-308.
10. Hiraoka, K., Miyamoto, M., Cho, Y., Suzuoki, M., Oshikiri, T., Nakakubo, Y., Itoh, T., Ohbuchi, T., Kondo, S., Katoh, H. (2006) Concurrent infiltration by CD8 T cells and CD4 T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br. J. Cancer 94, 275-280.
11. Al-Shibli, K. I., Donnem, T., Al-Saad, S., Persson, M., Bremnes, R. M., Busund, L. T. (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 14, 5220-5227.
12. Zhuang, X., Xia, X., Wang, C., Gao, F., Shan, N., Zhang, L., Zhang, L. (2010) A high number of CD8 T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl. Immunohistochem. Mol. Morphol. 18, 24-28.
13. Kawai, O., Ishii, G., Kubota, K., Murata, Y., Naito, Y., Mizuno, T., Aokage, K., Saijo, N., Nishiwaki, Y., Gemma, A., Kudoh, S., Ochiai, A. (2008) Predominant infiltration of macrophages and CD8()Tcellsin cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387-1395.
14. Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., June, C. H. (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276.
15. Shimizu, K., Nakata, M., Hirami, Y., Yukawa, T., Maeda, A., Tanemoto, K. (2010) Tumor-infiltrating Foxp3 regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J. Thorac. Oncol. 5, 585-590.
16. Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M. B., Harpole D. H., Jr., Patz E. F., Jr., (2006) Tumor infiltrating Foxp3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107, 2866-2872.
17. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., Sznol, M. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
18. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A., Wigginton, J. M. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
19. Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulieres, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., Davis, M., Mansi, J., Smith, C., Vergidis, D., Ellis, P., MacNeil, M., Palmer, M. (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23, 6674-6681.
20. Quoix, E., Ramlau, R., Westeel, V., Papai, Z., Madroszyk, A., Riviere, A., Koralewski, P., Breton, J. L., Stoelben, E., Braun, D., Debieuvre, D., Lena, H., Buyse, M., Chenard, M. P., Acres, B., Lacoste, G., Bastien, B., Tavernaro, A., Bizouarne, N., Bonnefoy, J. Y., Limacher, J. M. (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 12, 1125-1133.
21. Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264.
22. Fong, L., Small, E. J. (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26, 5275-5283.
23. Tarhini, A. A., Iqbal, F. (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 3, 15-25.
24. Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J. M., Reck, M. (2012) Ipilimumab in combination with Paclitaxel and Carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046-2054.
25. Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbe, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., Humphrey, R., Hodi, F. S. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420.
26. Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., Prevost-Blondel, A., Kato, M., Schultze, J. L., Tartour, E., Kroemer, G., Chaput, N., Zitvogel, L. (2011) IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71, 5393-5399.
27. Keir, M. E., Butte, M. J., Freeman, G. J., Sharpe, A. H. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704.
28. Reck, M. (2012) What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann. Oncol. 23 (Suppl. 8), viii28-viii34.
29. Zhang, Y., Huang, S., Gong, D., Qin, Y., Shen, Q. (2010) Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8 T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 7, 389-395.
30. Mu, C. Y., Huang, J. A., Chen, Y., Chen, C., Zhang, X. G. (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28, 682-688.
31. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., Lennon, V. A., Celis, E., Chen, L. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800.
32. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99, 12293-12297.
33. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., Tokura, Y. (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116, 1757-1766.
34. Yin, L., Li, Y., Ren, J., Kuwahara, H., Kufe, D. (2003) Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J. Biol. Chem. 278, 35458-35464.
35. Rahn, J. J., Chow, J. W., Horne, G. J., Mah, B. K., Emerman, J. T., Hoffman, P., Hugh, J. C. (2005) MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metastasis 22, 475-483.
36. Ho, S. B., Niehans, G. A., Lyftogt, C., Yan, P. S., Cherwitz, D. L., Gum, E. T., Dahiya, R., Kim, Y. S. (1993) Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53, 641-651.
37. Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., Lamport, D. (1987) Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47, 5476-5482.
38. Regimbald, L. H., Pilarski, L. M., Longenecker, B. M., Reddish, M. A., Zimmermann, G., Hugh, J. C. (1996) The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56, 4244-4249.
39. Situ, D., Wang, J., Ma, Y., Zhu, Z., Hu, Y., Long, H., Rong, T. (2011) Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med. Oncol. 28 (Suppl. 1), S596-S604.
40. Hall, R. D., Gray, J. E., Chiappori, A. A. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 20, 22-31.
41. Sangha, R., Butts, C. (2007) L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res. 13, s4652-s4654.
42. Samuel, J., Budzynski, W. A., Reddish, M. A., Ding, L., Zimmermann, G. L., Krantz, M. J., Koganty, R. R., Longenecker, B. M. (1998) Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer 75, 295-302.
43. Merck KGaA (2012) Press Release. Phase III Trial of L-BLP25 (Stimuvax) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint, Vol. 2013, Darmstadt, Germany.
44. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabárbara, P., Seymour, L., National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132.
45. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., Fukuoka, M. (2009) Gefitinib or CarboplatinPaclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957.
46. Gonzalez, G., Crombet, T., Catala, M., Mirabal, V., Hernandez, J. C., Gonzalez, Y., Marinello, P., Guillen, G., Lage, A. (1998) A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 9, 431-435.
47. Gonzalez, G., Crombet, T., Torres, F., Catala, M., Alfonso, L., Osorio, M., Neninger, E., Garcia, B., Mulet, A., Perez, R., Lage, R. (2003) Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol. 14, 461-466.
48. Neninger, E., Verdecia, B. G., Crombet, T., Viada, C., Pereda, S., Leonard, I., Mazorra, Z., Fleites, G., Gonzalez, M., Wilkinson, B., Gonzalez, G., Lage, A. (2009) Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 32, 92-99.
49. Rodriguez, P. C., Rodriguez, G., Gonzalez, G., Lage, A. (2010) Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for nonsmall-cell lung cancer therapy. MEDICC Rev. 12, 17-23.
50. Wigren, M., Bjorkbacka, H., Andersson, L., Ljungcrantz, I., Fredrikson, G. N., Persson, M., Bryngelsson, C., Hedblad, B., Nilsson, J. (2012) Low levels of circulating CD4 FoxP3 T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler. Thromb. Vasc. Biol. 32, 2000-2004.
51. Berg, K. E., Ljungcrantz, I., Andersson, L., Bryngelsson, C., Hedblad, B., Fredrikson, G. N., Nilsson, J., Bjorkbacka, H. (2012) Elevated CD14 CD16 monocytes predict cardiovascular events. Circ. Cardiovasc. Genet. 5, 122-131.
52. Auffray, C., Sieweke, M. H., Geissmann, F. (2009) Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 669-692.
53. Vansteenkiste, J., Zielinski, M., Linder, A., Dahabre, J., Esteban, E., Malinowski, W., Jassem, J., Passlick, B., Lehmann, F., Brichard, V. G. (2007) Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings (Post-Meeting Ed.). J. Clin. Oncol. 25, 7554.
54. Kong, F., Jirtle, R. L., Huang, D. H., Clough, R. W., Anscher, M. S. (1999) Plasma transforming growth factor1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86, 1712-1719.
55. Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., DeVol, E., Maples, P. B., Liu, L., Chamberlin, T., Shawler, D. L., Fakhrai, H. (2006) Phase II study of Belagenpumatucel-L, a transforming growth factor-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721-4730.